Mechanisms behind COX-1 and COX-2 inhibition of tumor growth in vivo

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1143-1152

  Axelsson, Hans ^a   Lönnroth, Christina ^a   Andersson, Marianne ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

COX 1; COX 2; EGF R; Prostanoids

Indexed keywords

CYCLINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; INDOMETACIN; JANUS KINASE 1; K RAS PROTEIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; PROTEIN P21; PROTEIN P27; PROTEIN P53; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA TRANSCRIPTION; TUMOR GROWTH;

EID: 77957868679     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000766     Document Type: Article

References (58)

1. Peterson HI: Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res 6: 251-253, 1986.
2. Peluffo GD, Stillitani I, Rodriguez VA, Diament MJ and Klein SM: Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 110: 825-830, 2004. (Pubitemid 38758507)
3. Gelin J, Andersson C and Lundholm K: Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 51: 880-885, 1991.
4. Sandstrom R, Gelin J and Lundholm K: The effect of indomethacin on food and water intake, motor activity and survival in tumour-bearing rats. Eur J Cancer 26: 811-814, 1990. (Pubitemid 20328554)
5. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O and Spano JP: Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59: 51-64, 2006. (Pubitemid 43903278)
6. Brown JR and DuBois RN: Cyclooxygenase as a target in lung cancer. Clin Cancer Res 10: S4266-S4269, 2004.
7. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K and Svanberg E: Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 60: 5488-5493, 2000.
8. McMillan DC, Leen E, Smith J, Sturgeon C, Preston T, Cooke TG and McArdle CS: Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 21: 531-534, 1995.
9. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B, Hafström L, Kewenter J, Olbe L and Lundell L: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602-5606, 1994. (Pubitemid 24346254)
10. Cahlin C, Gelin J, Delbro D, Lonnroth C, Doi C and Lundholm K: Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60: 1742-1749, 2000.
11. Lönnroth C, Svaninger G, Gelin J, Cahlin C, Iresjö B-M, Cvetkovska E, Edström S, Andersson M, Svanberg E and Lundholm K: Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int J Oncol 7: 1405-1413, 1995.
12. Lundholm K, Daneryd P, Korner U, Hyltander A and Bosaeus I: Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24: 505-512, 2004.
13. Limsukon A, Susanto I, Hoo GW, Dubinett SM and Batra RK: Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest 136: 924-926, 2009.
14. Wu R, Abramson AL, Shikowitz MJ, Dannenberg AJ and Steinberg BM: Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res 11: 6155-6161, 2005. (Pubitemid 41262942)
15. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G and Wagner SN: Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 6: 1066-1069, 2008.
16. Axelsson H, Lönnroth C, Wang W, Svanberg E and Lundholm K: Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice. Angiogenesis 8: 339-348, 2005. (Pubitemid 43312269)
17. Axelsson H, Bagge U, Lundholm K and Svanberg E: A one-piece plexiglass access chamber for subcutaneous implantation in the dorsal skin fold of the mouse. Int J Microcirc Clin Exp 17: 328-329, 1997. (Pubitemid 127791846)
18. Lönnroth C, Andersson M and Lundholm K: Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18: 929-937, 2001.
19. Rao M, Yang W, Seifalian AM and Winslet MC: Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int J Colorectal Dis 19: 1-11, 2004. (Pubitemid 38088279)
20. Gately S and Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004. (Pubitemid 38879409)
21. Nishimura M, Shin MS, Singhirunnusorn P, Suzuki S, Kawanishi M, Koizumi K, Saiki I and Sakurai H: TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol 29: 5529-5539, 2009.
22. Singh R, Lei P and Andreadis ST: PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering. Exp Cell Res 315: 2899-2913, 2009.
23. Adachi S, Shimizu M, Shirakami Y, Yamauchi J, Natsume H, Matsushima-Nishiwaki R, To S, Weinstein IB, Moriwaki H and Kozawa O: (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis 30: 1544-1552, 2009.
24. Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P and Kern MA: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 104: 171-181, 2009.
25. Chen L, He Y, Huang H, Liao H and Wei W: Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on nonsmall cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol 25: 161-171, 2008.
26. Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A and Sarkar FH: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 110: 2775-2784, 2007.
27. Banu N, Buda A, Chell S, Elder D, Moorghen M, Paraskeva C, Qualtrough D and Pignatelli M: Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Prolif 40: 768-779, 2007. (Pubitemid 47416549)
28. Sheng G, Guo J and Warner BW: Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 293: G599-G606, 2007. (Pubitemid 47435380)
29. Lanza-Jacoby S, Burd R, Rosato FE Jr, McGuire K, Little J, Nougbilly N and Miller S: Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin Cancer Res 12: 6161-6169, 2006. (Pubitemid 44703782)
30. Huh YH, Kim SH, Kim SJ and Chun JS: Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J Biol Chem 278: 9691-9697, 2003.
31. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL and Morrow JD: Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94: 657-662, 1997.
32. Chun KS and Surh YJ: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68: 1089-1100, 2004.
33. Breyer RM, Bagdassarian CK, Myers SA and Breyer MD: Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001.
34. Brown JR and DuBois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855, 2005. (Pubitemid 46179475)
35. Clevers H: Colon cancer - understanding how NSAIDs work. N Engl J Med 354: 761-763, 2006.
36. Sugimoto Y, Narumiya S and Ichikawa A: Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 39: 289-314, 2000. (Pubitemid 30336470)
37. Lundholm K, Edstrom S, Ekman L, Karlberg I, Bylund AC and Schersten T: A comparative study of the influence of malignant tumor on host metabolism in mice and man: evaluation of an experimental model. Cancer 42: 453-461, 1978. (Pubitemid 8405836)
38. Karlberg I, Edstrom S, Ekman L, Johansson S, Schersten T and Lundholm K: Metabolic host reaction in response to the proliferation of nonmalignant cells versus malignant cells in vivo. Cancer Res 41: 4154-4161, 1981. (Pubitemid 11011212)
39. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lonnroth C and Lundholm K: EP(1-4) subtype, COX and PPARgamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121: 232-240, 2007. (Pubitemid 46917690)
40. Auman JT, Church R, Lee SY, Watson MA, Fleshman JW and McLeod HL: Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 44: 1754-1760, 2008.
41. Chan AT, Ogino S and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658, 2009.
42. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C and Lundholm K: Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol 46: 1107-1112, 2007. (Pubitemid 350058890)
43. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
44. Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF and Powell DW: Subepithelial myofibroblasts express cyclooxygenase- 2 in colorectal tubular adenomas. Clin Cancer Res 10: 5870-5879, 2004. (Pubitemid 39180968)
45. Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K and Lundholm K: Preoperative treatment with a non-steroidal antiinflammaatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 8: 5, 2008. (Pubitemid 351507297)
46. Eisinger AL, Prescott SM, Jones DA and Stafforini DM: The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat 82: 147-154, 2007. (Pubitemid 44880176)
47. Negishi M, Sugimoto Y and Ichikawa A: Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1259: 109-119, 1995.
48. Axelsson H, Lönnroth C, Andersson M, Wang W and Lundholm K: Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. Cancer Inform 2: 199-213, 2007.
49. Garewal H, Ramsey L, Fass R, Hart NK, Payne CM, Bernstein H and Bernstein C: Perils of immunohistochemistry: variability in staining specificity of commercially available COX-2 antibodies on human colon tissue. Dig Dis Sci 48: 197-202, 2003. (Pubitemid 36232783)
50. Gustafsson A, Andersson M, Lagerstedt K, Lönnroth C, Nordgren S and Lundholm K: Receptor and enzyme expression for prostanoid metabolism in colorectal cancer as related to tumor tissue PGE2. Int J Oncol 36: 469-478, 2010.
51. Spencer AG, Woods JW, Arakawa T, Singer, II and Smith WL: Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 273: 9886-9893, 1998. (Pubitemid 28183086)
52. Vazquez-Tello A, Fan L, Hou X, Joyal JS, Mancini JA, Quiniou C, Clyman RI, Gobeil F Jr, Varma DR and Chemtob S: Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain. Am J Physiol Regul Integr Comp Physiol 287: R1155-R1163, 2004. (Pubitemid 39391060)
53. Cahlin C, Lönnroth C, Arvidsson A, Nordgren S and Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol 32: 909-918, 2008.
54. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR and Shin DM: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-6269, 2005.
55. Jin Y, Zhang C, Zeng W, Taya K and Tan TQ: Interactive actions of prostaglandin and epidermal growth factor to enhance proliferation of granulosa cells from chicken prehierarchical follicles. Prostaglandins Other Lipid Mediat 83: 285-294, 2007.
56. Buchanan FG, Holla V, Katkuri S, Matta P and DuBois RN: Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 67: 9380-9388, 2007.
57. Selvendiran K, Bratasz A, Tong L, Ignarro LJ and Kuppusamy P: NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle 7: 81-88, 2008.
58. Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H and Ichikawa T: Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 518: 154-158, 2002.